Pre-transplantation levels of lysine(K)-specific methyltransferase 2A(KMT2A)partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation  

作　　者：Dao-Xing Deng Xiao-Hang Ma Ze-Hua Wu Xiao-Hui Zhang Lan-Ping Xu Yu Wang Chen-Hua Yan Huan Chen Yu-Hong Chen Wei Han Feng-Rong Wang Jing-Zhi Wang Xiao-Jun Huang Xiao-Su Zhao Xiao-Dong Mo 

机构地区：[1]Peking University People’s Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing,China [2]Department of Hematology,Peking University Shenzhen Hospital,Shenzhen,China [3]Peking-Tsinghua Center for Life Sciences,Academy for Advanced Interdisciplinary Studies,Peking University,Beijing,China [4]Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies,Chinese Academy of Medical Sciences,2019RU029,Beijing,China

出　　处：《Blood Science》2024年第4期52-59,共8页血液科学(英文)

基　　金：supported by the National Key Research and Development Program of China(2021YFC2500300,2022YFC2502606);the Grants from the Beijing Municipal Science and Technology Commission(Z221100007422008);Major Program of the National Natural Science Foundation of China(82293630,82293633);CAMS Innovation Fund for Medical Sciences(2022-I2M-C&T-B-121,2023-I2MC&T-B-123);Peking University People’s Hospital Research and Development Funds(RD2023-08);Tongzhou District Distinguished Young Scholars(JCQN2023009);the Fundamental Research Funds for the Central Universities。

摘　　要：We aimed to identify dynamic changes of lysine(K)-specific methyltransferase 2A partial tandem duplications(KMT2A-PTD)before and after haploidentical donor hematopoietic stem cell transplantation(HID HSCT)and explore the prognostic value of pre-transplantation levels of KMT2A-PTD in acute myeloid leukemia(AML)receiving HID HSCT.Consecutive 64 AML patients with KMT2A-PTD positivity at diagnosis receiving HID HSCT were included in this study.Patients with KMT2A-PTD≥1%before HSCT had a slower decrease of KMT2A-PTD after HID HSCT.Patients with KMT2A-PTD≥1%before HID HSCT had a higher cumulative incidence of relapse(36.4%,95%confidence interval[CI]:6.3%-66.5%)at 2 years after HSCT than those with KMT2A-PTD<1%(7.5%,95%CI:0.3%-14.7%,P=.010).In multivariable analysis,KMT2A-PTD≥1%before HID HSCT was the only independent risk factor for relapse(hazard ratio[HR]:4.90;95%CI:1.22-19.59;P=.025).Thus,pre-transplantation levels of KMT2A-PTD could predict relapse in AML patients following HID HSCT.

关 键 词：Acute myeloid leukemia Allogeneic hematopoietic stem cell transplantation HAPLOIDENTICAL KMT2A-PTD RELAPSE 

分 类 号：R73[医药卫生—肿瘤]